Treatment of fibrosis

• US 10,106,603 B2
• Filed: 05/24/2018
• Issued: 10/23/2018
• Est. Priority Date: 12/16/2015
• Status: Active Grant

• Current Assignee: Singapore Health Services Pte Limited (MOH Holdings Pte Limited), National University of Singapore
• Original Assignee: Singapore Health Services Pte Limited (MOH Holdings Pte Limited), National University of Singapore
• Inventors: Cook, Stuart Alexander, Schaefer, Sebastian
• Primary Examiner(s): Mertz, Prema M
• Application Number:
  US15/988,463
• Publication Number:
  US 20180265579A1
• Time in Patent Office: 152 Days
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 2039/54 characterised by the route of administration
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 27/02 Ophthalmic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: C07K 14/5428 IL-10
• CPC Class Codes: C07K 14/7155 for interleukins [IL]
• CPC Class Codes: C07K 16/244 Interleukins [IL]
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons
• CPC Class Codes: C07K 2317/20 characterized by taxonomic origin
• CPC Class Codes: C07K 2317/21 from primates, e.g. man
• CPC Class Codes: C07K 2317/73 Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C07K 2319/00 Fusion polypeptide
• CPC Class Codes: C07K 2319/32 fusions with soluble part of a cell surface receptor, "decoy receptors"
• CPC Class Codes: C07K 2319/43 containing a FLAG-tag
• CPC Class Codes: C12N 15/1136 against growth factors, growth regulators, cytokines, lymphokines or hormones
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 2310/14 : interfering N.A.

Abstract

Aspects of the disclosure relate to the treatment, prevention or alleviation of conditions such as fibrosis in a subject. In some embodiments, the treatment, prevention or alleviation of fibrosis in a subject through the administration of an agent capable of inhibiting the action of Interleukin 11 (IL-11) is disclosed.

Claims

1. A method of treating fibrosis in the human subject, the method comprising administering to a human subject in need of treatment a therapeutically effective amount of an Interleukin 11 receptor α

(IL-11Rα

) antibody which is capable of inhibiting Interleukin 11 (IL-11) mediated signaling, wherein the fibrosis is fibrosis of the heart, liver, kidney or eye.

2. The method of claim 1, wherein the antibody is capable of inhibiting or reducing the binding of IL-11 to an IL-11 receptor.

3. The method of claim 1, wherein the antibody is an IL-11Rα

binding antibody.

4. The method of claim 1, wherein the fibrosis is in the heart and is associated with dysfunction of the musculature or electrical properties of the heart, or thickening of the walls or valves of the heart.

5. The method of claim 1, wherein the fibrosis is in the liver and is associated with chronic liver disease or liver cirrhosis.

6. The method of claim 1, wherein the fibrosis is in the kidney and is associated with chronic kidney disease.

7. The method of claim 1, wherein the fibrosis is in the eye and is retinal fibrosis, epiretinal fibrosis, or subretinal fibrosis.

8. The method of claim 1, wherein the method of treating fibrosis comprises administering said antibody to a subject in which IL-11Rα

expression is upregulated.

9. The method of claim 1, wherein the method of treating fibrosis comprises administering said antibody to a subject in which IL-11Rα

expression has been determined to be upregulated.

10. The method of claim 1, wherein the method of treating fibrosis comprises determining whether IL-11Rα

expression is upregulated in the subject and administering said antibody to a subject in which IL-11Rα

expression is upregulated.